Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sanofi to Start China Clinical Trial of Cancer Drug In-licensed from SIBS

publication date: May 25, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sanofi hopes to begin a Phase I clinical trial in China next year of a novel drug that targets liver cancer. The molecule inhibits the slit-robo signaling path that controls tumor vasculature and tumor growth, a discovery made by researchers at the Shanghai Institute of Biological Sciences (SIBS). Sanofi in-licensed global rights from SIBS to the molecule in 2010 for a reported $60 million upfront payment. More details....

Stock Symbol: (NYSE: SNY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...